Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22682925 | 0.94 | KMT2A (0.37) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL28897031 | 0.79 | HTR1A (0.43) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL771963 | 0.76 | — | — | |
| SCHEMBL7246530 | 0.75 | ALDH1A1 (0.32) | MAPT | |
| SCHEMBL2645020 | 0.75 | KDM4E (0.38) | MEN1KMT2A | |
| SCHEMBL3948863 | 0.74 | ALDH1A1 (0.48) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL18228341 | 0.74 | SMN1; SMN2 (0.32) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14645942 | 0.73 | MEN1 (0.35) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2645701 | 0.73 | HPGD (0.30) | — | |
| SCHEMBL5202206 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | MEN1 1453/4885KMT2A 2033/4885SMN1; SMN2 4447/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | MEN1 1870/4885KMT2A 1957/4885SMN1; SMN2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.